Insider Trading Alert - BLUE, BHI And HCP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 3, 2014, 85 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $4,255.74 to $5,989,983.27.

Highlighted Stocks Traded by Insiders:

bluebird bio (BLUE) - FREE Research Report

Leschly Nick, who is President and CEO at bluebird bio, sold 10,300 shares at $38.45 on Sept. 3, 2014. Following this transaction, the President and CEO owned 315,001 shares meaning that the stake was reduced by 3.17% with the 10,300-share transaction.

The shares most recently traded at $38.52, up $0.07, or 0.18% since the insider transaction. Historical insider transactions for bluebird bio go as follows:

  • 4-Week # shares bought: 2,941
  • 4-Week # shares sold: 8,000
  • 12-Week # shares bought: 2,941
  • 12-Week # shares sold: 90,283
  • 24-Week # shares bought: 2,941
  • 24-Week # shares sold: 105,283

The average volume for bluebird bio has been 553,900 shares per day over the past 30 days. Bluebird bio has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 81.27% year-to-date as of the close of trading on Wednesday.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company has a P/E ratio of 6.0. Currently, there are 3 analysts who rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BLUE - FREE

TheStreet Quant Ratings rates bluebird bio as a sell. The area that we feel has been the company's primary weakness has been its feeble growth in its earnings per share. Get the full bluebird bio Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

Cramer: There Should Be More Takeovers Where These Came From

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI